Consider patients' clinical features when choosing third-line drugs for type 2 diabetes

摘要

There is no clear difference in benefit between medicines added as a third treatment option for patients with type 2 diabetes who are already taking metformin and a sulfonylurea, according to a meta-analysis published in Annals of Internal Medicine (2011;154:672). However, an expert diabetes pharmacist has warned that the findings should be viewed cautiously, echoing reservations of the study authors themselves.